Integra lifesciences (NASDAQ:IART) VP Glenn Coleman sold 8,769 shares of the stock in a transaction dated Wednesday, March 14th. The shares were sold at an average price of $56.10, for a total transaction of $491,940.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Shares of NASDAQ IART opened at $54.59 on Friday. The company has a market cap of $4,390.97, a PE ratio of 28.14, a PEG ratio of 1.72 and a beta of 0.65. The company has a debt-to-equity ratio of 1.85, a current ratio of 2.36 and a quick ratio of 1.51. Integra lifesciences has a 1 year low of $40.59 and a 1 year high of $58.17.
Integra lifesciences (NASDAQ:IART) last announced its quarterly earnings results on Tuesday, February 27th. The life sciences company reported $0.64 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.56 by $0.08. The business had revenue of $368.60 million during the quarter, compared to the consensus estimate of $362.64 million. Integra lifesciences had a net margin of 5.45% and a return on equity of 16.94%. The business’s revenue was up 44.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.52 EPS. sell-side analysts expect that Integra lifesciences will post 2.33 EPS for the current fiscal year.
IART has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of Integra lifesciences from a “sell” rating to a “hold” rating in a report on Tuesday, December 26th. Oppenheimer set a $58.00 price objective on shares of Integra lifesciences and gave the company a “buy” rating in a report on Tuesday, December 12th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $52.00 price objective on shares of Integra lifesciences in a report on Friday, January 5th. BTIG Research initiated coverage on shares of Integra lifesciences in a report on Thursday. They issued a “neutral” rating and a $56.00 price objective for the company. Finally, TheStreet upgraded shares of Integra lifesciences from a “c+” rating to a “b-” rating in a report on Wednesday, February 7th. Eleven analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $54.82.
Several large investors have recently bought and sold shares of IART. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Integra lifesciences by 38.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,806 shares of the life sciences company’s stock worth $182,000 after purchasing an additional 1,054 shares during the period. Zions Bancorporation purchased a new position in shares of Integra lifesciences during the 3rd quarter worth approximately $205,000. Xact Kapitalforvaltning AB purchased a new position in shares of Integra lifesciences during the 4th quarter worth approximately $311,000. Campbell Newman Asset Management Inc. boosted its position in shares of Integra lifesciences by 21.5% during the 4th quarter. Campbell Newman Asset Management Inc. now owns 6,964 shares of the life sciences company’s stock worth $333,000 after purchasing an additional 1,234 shares during the period. Finally, Stone Ridge Asset Management LLC purchased a new position in shares of Integra lifesciences during the 4th quarter worth approximately $360,000. 90.93% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “Glenn Coleman Sells 8,769 Shares of Integra lifesciences (NASDAQ:IART) Stock” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US and international copyright and trademark laws. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/08/integra-lifesciences-holdings-corp-iart-vp-glenn-coleman-sells-8769-shares-of-stock.html.
Integra lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Receive News & Ratings for Integra lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.